A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

Emily Pwee, 54, developed a fever and cough on Oct. 10, her husband, 54-year-old Jimmy Teo, told Shin Min Daily News . Teo, a ...

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Corcept Therapeutics shares fell 0.9% in premarket trading Monday despite the company reporting late-breaking Phase 3 data ...

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements ...

Families, hospital employees, cancer patients, and survivors gathered on Sunday for the 10th annual Dominique Dagenais Cedars ...

Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean ...

Families, hospital employees, cancer patients, and survivors gathered on Sunday for the 10th annual Dominique Dagenais Cedars Run for Ovarian Cancer in TMR. The event raised funds for the DOvEEgene ...